Clinical Trials Logo

Clinical Trial Summary

In this study the researcher observe how vertigo symptoms change during two months of treatment with the natural medicinal product Vertigoheel©. Adult patients suffering from vertigo symptoms can participate if they are diagnosed with bilateral vestibulopathy (BVP) or functional dizziness (FD) and assigned to Vertigoheel treatment. Participating patients receive an examination at study start and after 2 months of Vertigoheel treatment. The study focuses on patient reported outcomes assessed by questionnaires. Vertigo symptoms are assessed by the Dizziness Handicap Inventory questionnaire. Patients' quality of life is assessed by a questionnaire. Body sway is assessed by static posturography. FD patients are additionally tested for depressive and anxiety symptoms by questionnaires. BVP patients are additionally tested for vestibular function by video head impulse test and caloric testing. Adverse events and other observations related to safety (physical examination and vital signs) are evaluated. Vertigo is a common symptom with significant adverse effects on patients' quality of life. Regardless of the exact cause of vertigo attacks, it is important to reduce the frequency, intensity, and duration of vertigo attacks with an effective medication that has no or minimal adverse effect. Vertigoheel®, a natural medicinal product consisting of four ponderable active ingredients, is approved in Germany as treatment for vertigo of various origins. However, no systematic data are available for Vertigoheel® regarding patient-reported outcomes in BVP and FD as the most accepted endpoint in vertigo studies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05897853
Study type Observational
Source Ludwig-Maximilians - University of Munich
Contact
Status Completed
Phase
Start date November 29, 2021
Completion date December 5, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Recruiting NCT05533840 - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Completed NCT02533739 - Vestibular Disorder and Visuo-spatial Functions N/A
Completed NCT01153789 - Study of Oculomotor Dysfunction Leading to Children Vertigo N/A
Completed NCT00765635 - Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal Phase 4
Not yet recruiting NCT04929444 - Training to Improve Vertigo Management in Primary Care N/A
Not yet recruiting NCT04055766 - A Diagnostic Test on DeepDoc-an AI-based Decision Support System
Completed NCT04458376 - Internet-based Self-help Program for Vestibular Rehabilitation in Chronic Dizziness N/A
Recruiting NCT06332326 - Investigation of the Efficacy of Non-Invasive Vagus Nerve Stimulation and Physiotherapy in Unilateral Vestibular Hypofunction Patients N/A
Completed NCT02938221 - Telemedical Examination of a Three-Component Oculomotor Testing Battery N/A
Active, not recruiting NCT02655575 - Assessment and Treatment of Patients With Long-term Dizziness in Primary Care N/A
Completed NCT02457455 - Urgent Medical and Surgical Conditions During Flights N/A
Enrolling by invitation NCT01426932 - The Head Impulse Test in the Screening of Vestibular Function N/A
Completed NCT00000359 - Treatments for Benign Paroxysmal Positional Vertigo (BPPV) Phase 2
Not yet recruiting NCT06017466 - Translation and Implementation of the Dutch VVAS Score in Clinical Practice N/A
Not yet recruiting NCT06010550 - Validating a Clinical Decision Support Tool for Stratifying Stroke Risk for Dizziness/Vertigo
Completed NCT04598113 - Effect of Cervical Traction on Balance in Cervical Radiculopathy Patients N/A
Completed NCT05157399 - Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness N/A
Completed NCT05221892 - Evaluation of Aminobutyric Acid, Glutamic Acid, Calcium, Thiamine, Pyridoxine and Cyanocobalamin as Therapy for Vertigo Phase 4
Completed NCT02253524 - Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo Phase 4